Filing Analysis
OnKure Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished under Item 2.02 of the Form 8-K.
Key Facts
- Financial results cover the quarter ended March 31, 2026.
- The report was filed on May 5, 2026.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Jason Leverone, Chief Financial Officer, signed the filing.
OnKure Therapeutics announced a $150 million private placement of common stock and pre-funded warrants at $4.15 per share. Simultaneously, the company disclosed a major strategic pivot, discontinuing independent development of its lead clinical asset OKI-219 to focus on next-generation candidates with IND filings planned for 2027.
Red Flags
- Significant dilution from the issuance of over 36 million shares/equivalents.
- Strategic abandonment of the current lead clinical asset (OKI-219) for independent development.
- Long lead time for new pipeline assets, with IND applications not expected until the first half of 2027.
Key Facts
- Entered into a Securities Purchase Agreement for approximately $150 million in gross proceeds.
- Issuing 26,713,636 shares of Class A common stock and 9,430,959 pre-funded warrants at $4.15 per unit.
- Lead investor AI Biotechnology LLC granted a board nominee right; Dr. Liam Ratcliffe appointed to the Board.
- Discontinuing independent clinical development of OKI-219 despite completing enrollment in Phase 1a/1b dose escalation.
- Shifting focus to next-generation PI3Kα pan-mutant programs OKI-345 and OKI-355, with IND applications expected in H1 2027.
- Executive officers and directors entered into 180-day lock-up agreements.
OnKure Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal disclosure of the company's year-end performance via a press release attached as an exhibit.
Key Facts
- The report was filed on March 12, 2026, covering the period ended December 31, 2025.
- The filing includes Item 2.02 (Results of Operations and Financial Condition).
- Jason Leverone, Chief Financial Officer, signed the filing.
- The company is classified as an emerging growth company.